Differential diagnosis of suspected multiple sclerosis: a consensus approachDH Miller, C.H. Polman, BG Weinshenker et al.|Multiple Sclerosis Journal|2008Cited by 643
Randomized, comparative study of interferon β-1a treatment regimens in MSHillel Panitch, Brian G. Weinshenker, Douglas S. Goodin et al.|Neurology|2002Cited by 633
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchangeMark Keegan, Claudia F. Lucchinetti, Hillel Panitch et al.|The Lancet|2005Cited by 430
Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trialHillel Panitch, Brian G. Weinshenker, Douglas S. Goodin et al.|Journal of the Neurological Sciences|2005Cited by 98